|
Sign In to gain access to subscriptions and/or personal tools.
|
Journal of Oncology Pharmacy Practice, Vol. 12, No. 3,
179-181 (2006)
DOI: 10.1177/1078155206069165
Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans
Myke R Green, PharmD
Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Claudio Anasetti, MD
Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Ramon L Sandin, MD
Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Nancy E Rolfe, ARNP
Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
John N Greene, MD
Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Daptomycin has demonstrated antibacterial activity against several antibiotic-resistant strains, including vancomycin-resistant enterococci.1 A paucity of data exists concerning in vivo development of daptomycin resistance of enterococci. We describe an allogeneic bone marrow transplant patient, who was found to have vancomycin-resistant Enterococcus durans bacteremia, which subsequently developed resistance to daptomycin.
Key Words: daptomycin • resistance • vancomycin-resistant enterococci • in vivo resistance • immuno-compromise
References
- Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains . Antimicrob Agents Chemother 2000; 44: 1062-1066 .[Abstract/Free Full Text]
- Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens . Clin Infect Dis 2004; 38: 994-1000 .[CrossRef][Medline]
[Order article via Infotrieve]
- Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections . J Antimicrob Agents Chemother 2000; 46: 523-526 .
- Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection . Clin Infect Dis 2005; 41: 565-566 .[CrossRef][Medline]
[Order article via Infotrieve]
- Long JK, Choueiri TK, Hall GS, et al. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia . Mayo Clin Proc 2005; 80: 1215-1216 .[Medline]
[Order article via Infotrieve]
- Sabol K, Patterson JE, Lewis JS, et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy . Antimicrob Agents Chemother 2005; 49: 1664-1665 .[Free Full Text]
- Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia . Clin Infect Dis 2005; 40: 1058-1060 .[CrossRef][Medline]
[Order article via Infotrieve]
- Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin . Antimicrob Agents Chemother 2001; 45: 1799-1802 .[Abstract/Free Full Text]
- Cui L, Tominaga E, Neoh H, et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus . Antimicrob Agents Chemother 2006; 50: 1079-1082 .[Abstract/Free Full Text]
- Jorgensen JH, Crawford SA, Kelly CC, et al. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods . Antimicrob Agents Che-mother 2003; 47: 3760-3763 .[Abstract/Free Full Text]
- Wise R, Andrews JM, Ashby JP. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint . J Antimicrob Chemother 2001; 48: 563-567 .[Abstract/Free Full Text]
- Johnson AP, Mushtaq S, Warner M, et al. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar . J Antimicrob Chemother 2004; 53: 860-862 .[Abstract/Free Full Text]
- Cubist Pharmaceuticals. Prescribing information on Cubicin®, daptomycin. Lexington, MA , 2005.
- Sica DA, Gehr T, Dvorchik BH. Pharmacokinetics and safety of single-dose daptomycin in subjects with graded renal insufficiency and end stage renal disease [abstract] . Program and abstracts of the forty-second interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, 27-30 September 2002. American Society for Microbiology, 2002: A-1387-A-1387 .
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. E. Warren
Daptomycin in endocarditis and bacteraemia: a British perspective
J. Antimicrob. Chemother.,
November 1, 2008;
62(suppl_3):
iii25 - iii33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Hidron, A. N. Schuetz, F. S. Nolte, C. V. Gould, and M. K. Osborn
Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis
J. Antimicrob. Chemother.,
June 1, 2008;
61(6):
1394 - 1396.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Arias, K. V. Singh, D. Panesso, and B. E. Murray
Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model
J. Antimicrob. Chemother.,
September 1, 2007;
60(3):
594 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Falagas, K. P. Giannopoulou, F. Ntziora, and K. Z. Vardakas
Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence
J. Antimicrob. Chemother.,
July 1, 2007;
60(1):
7 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
